ECOG-ACRIN 2108: Phase III Trial Evaluating the Role of Early Local Therapy for Patients With Metastatic Breast Cancer and an Intact Primary Tumor

May 29-31, 2020; Online at meetings.asco.org/am
Addition of early local therapy to systemic therapy for intact primary tumors in patients with de novo MBC was not associated with a survival benefit vs continued systemic therapy alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 253 KB
Released: June 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Dr Yara Abdou discusses BRCA mutation testing and adjuvant therapy with olaparib in BRCA-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: May 17, 2022 Expired: May 16, 2023

Slideset from Dr Yara Abdou on adjuvant olaparib in BRCA1/2-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Released: May 17, 2022

Dr. Yara Abdou discusses Ki-67 testing and adjuvant abemaciclib in HR+/HER2-, node-positive, high-risk early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 12, 2022 Expired: May 11, 2023

Slideset from Dr. Yara Abdou on Ki-67 and adjuvant abemaciclib for HR+/HER2-, node-positive, high-risk EBC, from Clinical Care Options (CCO)

Yara Abdou, MD Released: May 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings